

**The Arab Pesticides & Veterinary Drugs Mfg. Co.**  
**Public Shareholding Company**  
**Condensed Interim Consolidated Financial Statements (Unaudited)**  
**30 June 2025**

**The Arab Pesticides & Veterinary Drugs Mfg. Co.**  
**Public Shareholding Company**

---

|   | <u>Pages</u> |
|---|--------------|
| - Report on review of condensed interim consolidated financial statements | 2            |
| - Interim consolidated statement of financial position                    | 3            |
| - Interim consolidated statement of profit or loss                        | 4            |
| - Interim consolidated statement of comprehensive income                  | 5            |
| - Interim consolidated statement of changes in equity                     | 6            |
| - Interim consolidated statement of cash flows                            | 7            |
| - Notes to the condensed interim consolidated financial statements        | 8 - 10       |



**Report on Review of Condensed Interim Consolidated Financial Statements**

**To The Board of Directors  
The Arab Pesticides & Veterinary Drugs Mfg. Co.  
Public Shareholding Company  
Irbid - Jordan**

**Introduction**

We have reviewed the accompanying condensed interim consolidated financial statements of **The Arab Pesticides & Veterinary Drugs Mfg. Co. PLC**, comprising the interim consolidated statement of financial position as at 30 June 2025 and the related interim consolidated statement of profit or loss, interim consolidated statement of comprehensive income, interim consolidated statement of changes in equity and interim consolidated statement of cash flows for the six-months period then ended and the notes about condensed interim consolidated financial statements. Management is responsible for the preparation and presentation of this condensed interim consolidated financial statement in accordance with International Accounting Standard number (34) "Interim Financial Reporting". Our responsibility is to express a conclusion on this condensed interim consolidated financial statements based on our review.

**Scope of Review**

We conducted our review in accordance with the International Standard on Review Engagements number (2410) "Review of Interim Financial Information Performed by the Independent Auditor of the Entity." A review of condensed interim consolidated financial statement consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

**Conclusion**

Based on our review, nothing has come to our attention that causes us to believe that the accompanying condensed interim consolidated financial statement is not prepared, in all material respects, in accordance with International Accounting Standard number (34) "Interim Financial Reporting".

29 July 2025  
Amman - Jordan



**Arab Professionals  
Ibrahim Hammoudeh  
License No. (606)**



**The Arab Pesticides & Veterinary Drugs Mfg. Co.**  
**Public Shareholding Company**  
**Interim Consolidated Statement of Financial Position as at 30 June 2025**  
**(In Jordanian Dinar)**

|   | Note | 30 June<br>2025<br>(Unaudited) | 31 December<br>2024<br>(Audited) |
|---|------|--------------------------------|----------------------------------|
| <b>Assets</b>   |      |                                |                                  |
| <b>Non - current assets</b>                                       |      |                                |                                  |
| Property, plant and equipment                                     |      | 8,881,767                      | 8,669,432                        |
| Projects under construction                                       |      | 4,068,786                      | 3,705,335                        |
| Investment in associate   |      | 577,911                        | 630,346                          |
| Checks under collection – long term                               |      | 85,000                         | -                                |
| Financial assets at fair value through other comprehensive income |      | 237,090                        | 237,090                          |
| <b>Total non - current assets</b>                                 |      | <u>13,850,554</u>              | <u>13,242,203</u>                |
| <b>Current assets</b>   |      |                                |                                  |
| Inventory   |      | 18,009,202                     | 16,998,535                       |
| Other current assets  |      | 2,738,096                      | 2,347,059                        |
| Accounts receivable   |      | 16,579,636                     | 14,070,620                       |
| Checks under collection – short term                              |      | 2,062,377                      | 2,233,867                        |
| Amounts due from related parties                                  |      | 1,197,000                      | -                                |
| Cash and cash equivalents   |      | 6,780,989                      | 8,203,010                        |
| <b>Total current assets</b>                                       |      | <u>47,367,300</u>              | <u>43,853,091</u>                |
| <b>Total assets</b>   |      | <u><b>61,217,854</b></u>       | <u><b>57,095,294</b></u>         |
| <b>Equity and liabilities</b>                                     |      |                                |                                  |
| <b>Equity</b>   |      |                                |                                  |
| Paid - in capital   |      | 16,500,000                     | 16,500,000                       |
| Additional paid in capital  |      | 1,500,000                      | 1,500,000                        |
| Statutory reserve   |      | 4,125,000                      | 4,125,000                        |
| Voluntary reserve   |      | 2,118,949                      | 2,118,949                        |
| Changes in foreign exchange rate                                  |      | (3,112,354)                    | (3,095,919)                      |
| Retained earnings   | 4    | <u>16,841,245</u>              | <u>15,373,503</u>                |
| <b>Total Shareholder's Equity</b>                                 |      | 37,972,840                     | 36,521,533                       |
| Non-controlling interest  |      | <u>8,997,516</u>               | <u>8,727,356</u>                 |
| <b>Total equity</b>   |      | <u>46,970,356</u>              | <u>45,248,889</u>                |
| <b>Liabilities</b>  |      |                                |                                  |
| <b>Non - current liabilities</b>                                  |      |                                |                                  |
| Credit facilities – long term                                     |      | 2,607,911                      | 2,786,182                        |
| Notes payable – long term   |      | 35,230                         | 76,070                           |
| Provision for end of services indemnity                           |      | 453,574                        | 522,272                          |
| <b>Total non - current liabilities</b>                            |      | <u>3,096,715</u>               | <u>3,384,524</u>                 |
| <b>Current liabilities</b>  |      |                                |                                  |
| Credit facilities – short term                                    |      | 4,119,854                      | 3,183,843                        |
| Notes payable – short term  |      | 690,527                        | 1,170,849                        |
| Postdated checks  |      | 137,628                        | 144,151                          |
| Accounts payable  |      | 4,969,032                      | 2,190,235                        |
| Other current liabilities   |      | 1,233,742                      | 1,772,803                        |
| <b>Total current liabilities</b>                                  |      | <u>11,150,783</u>              | <u>8,461,881</u>                 |
| <b>Total liabilities</b>  |      | <u>14,247,498</u>              | <u>11,846,405</u>                |
| <b>Total equity and liabilities</b>                               |      | <u><b>61,217,854</b></u>       | <u><b>57,095,294</b></u>         |

“The accompanying notes from (1) to (5) are an integral part of these condensed interim consolidated financial statements and read with review report”

**The Arab Pesticides & Veterinary Drugs Mfg. Co.**  
**Public Shareholding Company**  
**Interim Consolidated Statement of Profit or Loss**  
**For the Six Months Ended at 30 June 2025 (Unaudited)**

(In Jordanian Dinar)

|  | Note | For the three months ended |                  | For the six months ended |                  |
|--|------|----------------------------|------------------|--------------------------|------------------|
|  |      | 30 June<br>2025            | 30 June<br>2024  | 30 June<br>2025          | 30 June<br>2024  |
| Net sales  |      | 9,273,332                  | 8,127,108        | 18,330,126               | 16,296,444       |
| Cost of sales  |      | (6,171,674)                | (5,365,799)      | (12,044,334)             | (10,569,034)     |
| <b>Gross profit</b>  |      | <b>3,101,658</b>           | <b>2,761,309</b> | <b>6,285,792</b>         | <b>5,727,410</b> |
| Share of profit from the associate company results                           |      | 39,345                     | 104,288          | 70,500                   | 173,099          |
| Selling and distribution expenses  |      | (293,715)                  | (233,323)        | (661,547)                | (506,832)        |
| Administrative expenses  |      | (533,098)                  | (567,368)        | (1,049,125)              | (1,096,265)      |
| Financing cost   |      | (73,959)                   | (85,070)         | (164,844)                | (163,232)        |
| Provision for expected credit loss   |      | -                          | -                | (100,000)                | (100,000)        |
| Net other income   |      | 1,939                      | 11,360           | 105,915                  | 60,327           |
| Provision for slow moving and expired inventories                            |      | -                          | -                | (50,000)                 | (100,000)        |
| <b>Profit before income tax for the period</b>                               |      | <b>2,242,170</b>           | <b>1,991,196</b> | <b>4,436,691</b>         | <b>3,994,507</b> |
| Income and National contribution tax for the period                          | 3    | (167,311)                  | (132,044)        | (345,139)                | (263,623)        |
| <b>Profit for the period</b>   |      | <b>2,074,859</b>           | <b>1,859,152</b> | <b>4,091,552</b>         | <b>3,730,884</b> |
| <b>Attributable to:</b>  |      |                            |                  |                          |                  |
| Shareholders of the Company  |      | 1,629,491                  | 1,522,238        | 3,282,742                | 2,960,589        |
| Non-controlling interest   |      | 445,368                    | 336,914          | 808,810                  | 770,295          |
|  |      | <b>2,074,859</b>           | <b>1,859,152</b> | <b>4,091,552</b>         | <b>3,730,884</b> |
| <b>Basic and diluted earnings per share attributable to the shareholders</b> |      | <b>0.099</b>               | <b>0.092</b>     | <b>0.199</b>             | <b>0.179</b>     |

"The accompanying notes from (1) to (5) are an integral part of these condensed interim consolidated financial statements and read with review report"

**The Arab Pesticides & Veterinary Drugs Mfg. Co.**  
**Public Shareholding Company**  
**Interim Consolidated Statement of Comprehensive Income**  
**For the Six Months Ended at 30 June 2025 (Unaudited)**

(In Jordanian Dinar)

|  | For the three months ended |                         | For the six months ended |                         |
|--|----------------------------|-------------------------|--------------------------|-------------------------|
|  | 30 June<br>2025            | 30 June<br>2024         | 30 June<br>2025          | 30 June<br>2024         |
| Profit for the period                            | 2,074,859                  | 1,859,152               | 4,091,552                | 3,730,884               |
| <b>Other comprehensive income item:</b>          |                            |                         |                          |                         |
| Changes in foreign exchange rate                 | (35,273)                   | -                       | (16,435)                 | (86,451)                |
| <b>Total comprehensive income for the period</b> | <b><u>2,039,586</u></b>    | <b><u>1,859,152</u></b> | <b><u>4,075,117</u></b>  | <b><u>3,644,433</u></b> |
| <b>Attributable to:</b>                          |                            |                         |                          |                         |
| Shareholders of the Company                      | 1,594,218                  | 1,522,238               | 3,266,307                | 2,874,138               |
| Non-controlling interest                         | 445,368                    | 336,914                 | 808,810                  | 770,295                 |
|  | <b><u>2,039,586</u></b>    | <b><u>1,859,152</u></b> | <b><u>4,075,117</u></b>  | <b><u>3,644,433</u></b> |

"The accompanying notes from (1) to (5) are an integral part of these condensed interim consolidated financial statements and read with review report"

**The Arab Pesticides & Veterinary Drugs Mfg. Co.**  
**Public Shareholding Company**  
**Interim Consolidated Statement of Changes in Equity for the Six Months Ended at 30 June 2025 (Unaudited)**  
**(In Jordanian Dinar)**

|  | <u>Paid - in<br/>Capital</u> | <u>Additional paid<br/>in capital</u> | <u>Reserves</u>         |                         | <u>Changes in<br/>Foreign<br/>Exchange Rate</u> | <u>Retained<br/>Earnings</u> | <u>Total<br/>Shareholders<br/>Equity</u> | <u>Non-<br/>Controlling<br/>Interest</u> | <u>Total<br/>Equity</u>  |
|--|------------------------------|---------------------------------------|-------------------------|-------------------------|---|------------------------------|--|--|--------------------------|
|  |                              |                                       | <u>Statutory</u>        | <u>Voluntary</u>        |   |                              |  |  |                          |
| <b>Balance at 1 January 2025</b>               | <b>16,500,000</b>            | <b>1,500,000</b>                      | <b>4,125,000</b>        | <b>2,118,949</b>        | <b>(3,095,919)</b>                              | <b>15,373,503</b>            | <b>36,521,533</b>                        | <b>8,727,356</b>                         | <b>45,248,889</b>        |
| Company's shareholders dividends paid (Note 4) | -                            | -                                     | -                       | -                       | -   | (1,815,000)                  | <b>(1,815,000)</b>                       | -  | <b>(1,815,000)</b>       |
| Non-controlling interest dividends paid        | -                            | -                                     | -                       | -                       | -   | -                            | -  | (538,650)                                | <b>(538,650)</b>         |
| Total comprehensive income for the period      | -                            | -                                     | -                       | -                       | (16,435)  | 3,282,742                    | <b>3,266,307</b>                         | 808,810                                  | <b>4,075,117</b>         |
| <b>Balance at 30 June 2025</b>                 | <b><u>16,500,000</u></b>     | <b><u>1,500,000</u></b>               | <b><u>4,125,000</u></b> | <b><u>2,118,949</u></b> | <b><u>(3,112,354)</u></b>                       | <b><u>16,841,245</u></b>     | <b><u>37,972,840</u></b>                 | <b><u>8,997,516</u></b>                  | <b><u>46,970,356</u></b> |
| <b>Balance at 1 January 2024</b>               | <b>16,500,000</b>            | <b>1,500,000</b>                      | <b>4,125,000</b>        | <b>2,118,949</b>        | <b>(3,009,469)</b>                              | <b>11,323,311</b>            | <b>32,557,791</b>                        | <b>7,440,116</b>                         | <b>39,997,907</b>        |
| Company's shareholders dividends paid          | -                            | -                                     | -                       | -                       | -   | (1,650,000)                  | <b>(1,650,000)</b>                       | -  | <b>(1,650,000)</b>       |
| Non-controlling interest dividends paid        | -                            | -                                     | -                       | -                       | -   | -                            | -  | (115,425)                                | <b>(115,425)</b>         |
| Total comprehensive income for the period      | -                            | -                                     | -                       | -                       | (86,451)  | 2,960,589                    | <b>2,874,138</b>                         | 770,295                                  | <b>3,644,433</b>         |
| <b>Balance at 30 June 2024</b>                 | <b><u>16,500,000</u></b>     | <b><u>1,500,000</u></b>               | <b><u>4,125,000</u></b> | <b><u>2,118,949</u></b> | <b><u>(3,095,920)</u></b>                       | <b><u>12,633,900</u></b>     | <b><u>33,781,929</u></b>                 | <b><u>8,094,986</u></b>                  | <b><u>41,876,915</u></b> |

"The accompanying notes from (1) to (5) are an integral part of these condensed interim consolidated financial statements and read with review report"

**The Arab Pesticides & Veterinary Drugs Mfg. Co.**  
**Public Shareholding Company**  
**Interim Consolidated Statement of Cash Flows**  
**For the Six Months Ended at 30 June 2025 (Unaudited)**

(In Jordanian Dinar)

|   | 30 June<br>2025         | 30 June<br>2024         |
|---|-------------------------|-------------------------|
| <b>Operating activities</b>                         |                         |                         |
| Profit for the period before income tax             | 4,436,691               | 3,994,507               |
| Depreciation  | 278,423                 | 259,883                 |
| Share of profit from the associate company results  | (70,500)                | (173,099)               |
| Provision for expected credit loss                  | 100,000                 | 100,000                 |
| Provision for slow moving and expired inventories   | 50,000                  | 100,000                 |
| Provision against end of service indemnity          | (68,698)                | (117,576)               |
| <b>Changes in working capital</b>                   |                         |                         |
| Checks under collection                             | 86,490                  | (258,841)               |
| Accounts receivable                                 | (2,609,016)             | (1,303,817)             |
| Inventory   | (1,060,667)             | (18,781)                |
| Other current assets                                | (391,037)               | (369,272)               |
| Accounts payable                                    | 2,778,797               | 1,620,601               |
| Amounts due from related parties                    | (1,197,000)             | -                       |
| Postdated checks                                    | (6,523)                 | (97,764)                |
| Other current liabilities                           | (539,061)               | (705,012)               |
| Income tax paid                                     | (345,139)               | (139,684)               |
| <b>Net cash flows from operating activities</b>     | <u>1,442,760</u>        | <u>2,891,145</u>        |
| <b>Investing activities</b>                         |                         |                         |
| Property, plant and equipment                       | (490,758)               | (1,025,649)             |
| Investment in associate dividends                   | 106,500                 | 106,500                 |
| Project under construction                          | (363,451)               | (581,634)               |
| <b>Net cash flows used in investing activities</b>  | <u>(747,709)</u>        | <u>(1,500,783)</u>      |
| <b>Financing activities</b>                         |                         |                         |
| Credit facilities                                   | 757,740                 | 2,025,841               |
| Notes payable                                       | (521,162)               | (742,857)               |
| Non-controlling interest dividends paid             | (538,650)               | (115,425)               |
| Company's shareholders dividends paid               | (1,815,000)             | (1,650,000)             |
| <b>Net cash flows used in financing activities</b>  | <u>(2,117,072)</u>      | <u>(482,441)</u>        |
| <b>Net changes in cash and cash equivalents</b>     | (1,422,021)             | 907,921                 |
| Cash and cash equivalents, beginning of the year    | 8,203,010               | 4,481,081               |
| <b>Cash and cash equivalents, end of the period</b> | <u><u>6,780,989</u></u> | <u><u>5,389,002</u></u> |

"The accompanying notes from (1) to (5) are an integral part of these condensed interim consolidated financial statements and read with review report"



**The Arab Pesticides & Veterinary Drugs Mfg. Co.**  
**Public Shareholding Company**  
**Notes to the Condensed Interim Consolidated Financial Statements (Unaudited)**  
**30 June 2025**

(In Jordanian Dinar)

**1 . General**

The Arab Pesticides & Veterinary Drugs Mfg. Co. was established as a Limited Liability Company on 17 October 1991 and on 31/7/2005 the Company changed its legal identity to a Public Shareholding Company, and registered in the Hashemite Kingdom of Jordan under number (366), with the main objective of manufacturing of pesticides and veterinary medicines.

The Company shares are listed in Amman Stock Exchange – Jordan.

The condensed interim consolidated financial statements have been approved for issue by the Company's Board of Directors on 28 July 2025.

**2 . Summary of Significant Accounting Policies**

**Basis of Preparation**

The condensed interim consolidated financial statements of the Company have been prepared in accordance with International Accounting Standard number (34) "Interim Financial Reporting". They do not include all of the information required in annual financial statements in accordance with IFRSs, and should be read in conjunction with the consolidated financial statements of the Company for the year ended 31 December 2024.

The condensed interim consolidated financial statements have been prepared on a historical cost basis except for financial assets at fair value.

The condensed interim consolidated financial statements are presented in Jordanian Dinar which is the functional currency of the Company.

The accounting policies are consistent with those used in the previous period, except for the adoption of new and amended standards effective as at the beginning of the year.

**Principles of Consolidation**

The condensed interim consolidated financial statements comprise of the financial statements of the parent and its subsidiaries where the Company has the power to govern the financial and operating policies of the subsidiaries so as to obtain benefits from their activities. The financial statements of the subsidiaries are prepared for the same reporting year as the Company using consistent accounting policies. All balances, transactions, income, and expenses between the Company and its subsidiaries are eliminated.

Subsidiaries are fully consolidated from the date of acquisition, being the date on which the Company obtains control, and continue to be consolidated until the date that such control ceases.

The results of operations of the subsidiaries are included in the consolidated statement of comprehensive income from the acquisition date which is the date on which control over subsidiary is transferred to the Company. The results of operation of the disposed subsidiary are included in the consolidated statement of comprehensive income to the disposal date which is the date on which the Company loses control over the subsidiary.

The following subsidiaries have been consolidated:

| Company   | Registration country | Ownership | Capital-JOD | Activity      |
|---|----------------------|-----------|-------------|---------------|
| Endmaj for Medical and Chemical Manufacturing Company | Jordan               | 100%      | 50,000      | Manufacturing |
| Delta Sudia Manufacturing Company                     | KSA                  | 55%       | 9,500,000   | Manufacturing |

### **Use of Estimates**

The preparation of the condensed interim consolidated financial statements requires management to make estimates and assumptions that affect the reported amount of the financial assets and liabilities and disclosure of contingent liabilities. These estimates and assumptions also affect the revenues and expenses and the resultant provisions and in particular, considerable judgment by management is required in the estimation of the amount and timing of future cash flows. Such estimates are necessarily based on assumptions about several factors involving varying degrees of judgment and uncertainty and actual results may differ resulting in future changes in such provisions.

Management believes that the estimates are reasonable and are as follows:

- Management reviews periodically the tangible assets in order to assess the depreciation for the year based on the useful life and future economic benefits. Any impairment is taken to the interim consolidated statement of profit or loss.
- The measurement of impairment losses under IFRS 9 requires judgment, in particular, the estimation of the amount and timing of future cash flows and collateral values when determining impairment losses and the assessment of a significant increase in credit risk. These estimates are driven by a number of factors, changes in which can result in different levels of allowances. Elements of the expected credit loss model that are considered accounting judgments and estimates include Probability of default (PD), Loss given default (LGD) and Exposure at default (EAD).
- Inventories are held at the lower of cost and net realizable value. When inventories become old or obsolete, an estimate is made of their net realizable value. For individually significant amounts this estimation is performed on an individual basis. Amounts which are not individually significant, but which are old or obsolete, are assessed collectively and a provision applied according to the inventory type and the degree of ageing or obsolescence, based on historical selling prices.

### **3 . Income Tax**

- The Company has settled its tax liabilities with the Income Tax Department up to the year ended 2019.
- The income tax return for the year 2020 was reviewed by the Income Tax Department, but the Department has not yet issued its final decision.
- The income tax returns for the years 2021, 2022, 2023 and 2024 has been filed with the Income Tax Department, but the Department has not reviewed the Company's records till the date of this report.
- The Income and National Contribution tax provision for six months ended at 30 June 2025 was calculated in accordance with the Income Tax Law.

### **4 . Dividends**

The General Assembly has resolved in its ordinary meeting held in 20 April 2025 to distribute (11%) cash dividends to shareholders.

## 5 . Fair Value of Financial instruments

The fair values of the financial assets and liabilities are not materially different from their carrying values as most of these items are either short-term in nature or re-priced frequently.

Financial assets and financial liabilities measured at fair value in the interim consolidated statement of financial position are grouped into three levels of a fair value hierarchy. The three levels are defined based on the observability of significant inputs to the measurement, as follows:

- Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities.
- Level 2: inputs other than quoted prices included within level 1 that are observable for the asset or liability, either directly or indirectly.
- Level 3: unobservable inputs for the asset or liability.

| <u>30 June 2025</u>   | <u>Level 1</u> | <u>Level 2</u> | <u>Level 3</u> | <u>Total</u>   |
|---|----------------|----------------|----------------|----------------|
| Financial assets at fair value through other comprehensive income | -              | -              | 237,090        | <u>237,090</u> |

| <u>31 December 2024</u>   | <u>Level 1</u> | <u>Level 2</u> | <u>Level 3</u> | <u>Total</u>   |
|---|----------------|----------------|----------------|----------------|
| Financial assets at fair value through other comprehensive income | -              | -              | 237,090        | <u>237,090</u> |

Financial assets included in level 3 are stated at cost less impairment charges, as the fair value of these assets cannot be measured reliably due to the lack of available active markets for identical assets.